EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Torque Teno virus is predictive for malignancies after kidney transplantation

Carsten T Herz, Frederik Haupenthal, Felix Herkner, Konstantin Doberer, Sebastian Kapps, Michael Eder, Robert Strassl, Anna S Bergmeister-Berghoff, Alexandra Geusau, Stephan Polterauer, Irene Görzer, Elisabeth Puchhammer-Stöckl, Gregor Bond

Nephrology Dialysis Transplantation · 2026-10-30 · 41 (11) · 2053-2061

DOI: 10.1093/ndt/gfag078 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background and hypothesis Malignancy, driven by the effects of immunosuppression, is a major complication following kidney transplantation. The widespread and non-pathogenic Torque Teno virus (TTV) has emerged as a surrogate of the immune status of its host, with prior studies linking TTV load to insufficient and excessive immunosuppression and thus indirectly to graft rejection and infection. Its relationship to malignancy in kidney transplant recipients is unknown. Methods This prospective observational single center study evaluated 428 patients who underwent kidney transplantation between 2016 and 2019 at the General Hospital of Vienna, Austria. TTV was measured by quantitative polymerase chain reaction in plasma and the primary outcome was the incidence of the first malignancy during years 2–5 post-transplant. Results In total, 53 patients developed malignancy (53% cutaneous keratinocyte cancer). The mean log10 TTV load during months 4 to 12 post-transplant (logTTVm4–12) was associated with increased malignancy risk with a hazard ratio (HR) of 1.25 [95% confidence interval (CI) 1.02–1.54] in unadjusted analysis and 1.20 (95% CI 0.97–1.48) after adjustment for age, sex, smoking, and body mass index. In a subgroup, the result remained consistent after additional adjustment for tacrolimus and mycophenolate exposure (HR 1.31, 95% CI 1.03–1.67). Patients with logTTVm4–12 >8, a cut-off we previously proposed to indicate infection risk, had an HR of 2.10 (95% CI 1.22–3.60). Conclusions These findings suggest that a high TTV load—indicating a state of intense immunosuppression—predicts malignancy after kidney transplantation. Monitoring TTV as a marker of immunosuppression may offer a novel strategy for personalizing immunosuppressive therapy and reducing cancer risk.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →